The Apex Times
Above the Noise
Business Wire
BusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessVenezuela’s energy reopening talks could create upside for Chevron and GE Vernova, but agreements still face major hurdlesThe Apex TimesBusinessTrump Says ExxonMobil Is Preparing to Re-enter Venezuela as Investment Outlook ShiftsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessVenezuela’s energy reopening talks could create upside for Chevron and GE Vernova, but agreements still face major hurdlesThe Apex TimesBusinessTrump Says ExxonMobil Is Preparing to Re-enter Venezuela as Investment Outlook ShiftsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessVenezuela’s energy reopening talks could create upside for Chevron and GE Vernova, but agreements still face major hurdlesThe Apex TimesBusinessTrump Says ExxonMobil Is Preparing to Re-enter Venezuela as Investment Outlook ShiftsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessVenezuela’s energy reopening talks could create upside for Chevron and GE Vernova, but agreements still face major hurdlesThe Apex TimesBusinessTrump Says ExxonMobil Is Preparing to Re-enter Venezuela as Investment Outlook ShiftsThe Apex Times
Back to front
Myriad Genetics and Moderna slide as biotech profit-taking cools a powerful run
The Apex Times

THE APEX TIMES

Business/The Apex Times/Aug 24, 5:01 PM EDT

Myriad Genetics and Moderna slide as biotech profit-taking cools a powerful run

Shares of Myriad Genetics and Moderna fell in the afternoon session as traders took gains and sentiment in biotech and big pharma cooled after a broad surge.

By The Apex Times Newsroom2 min readAI-assisted Apex article

Biotech and large pharmaceutical stocks gave back ground in the afternoon session, with Myriad Genetics and Moderna among the names seeing sharp declines. The selloff reflected a familiar pattern after an unusually strong period for the sector, as traders reduced exposure and secured profits rather than chasing momentum.

The weakness came after investors pushed the group higher earlier on optimism around clinical and product progress for the industry. As that enthusiasm cooled, many of the sector’s higher-beta stocks were hit harder, according to the market report.

Myriad Genetics, a company known for oncology-focused genetic testing services and related clinical decision support, was among those trading lower. The move suggested investors were reassessing near-term expectations, even as longer-term themes such as personalized cancer screening and targeted treatment selection remain central to the business.

Moderna, whose core business is centered on messenger RNA (mRNA) therapeutics and vaccines, also fell. Moderna’s valuation and trading have often been tied to investor expectations about the timing and scale of demand for its product pipeline, as well as the market’s broader risk appetite for biotech stocks.

Both companies’ moves fit the pattern of sector-wide pullbacks rather than isolated company-specific disclosures in the report. In other words, the shared direction pointed more to market positioning and trading behavior than to a single new adverse headline being cited in the afternoon write-up.

The broader healthcare backdrop matters because biotech tends to trade like a momentum and sentiment complex, not just on current earnings. When the sector has been rising quickly, even small changes in expectations about timelines, outcomes, or product adoption can lead to outsized swings, especially in stocks with high perceived growth and uncertainty.

Still, investors may note that the post did not provide detail on what drove the declines for Myriad Genetics and Moderna specifically, such as fresh regulatory updates, trial results, or guidance changes. Without that information, the most supportable conclusion is that profit-taking played a meaningful role in the afternoon moves described.

What to watch next is whether the weakness extends beyond intraday trading into subsequent sessions, and whether any new company updates emerge that change the narrative for Moderna’s pipeline and Myriad’s testing and oncology strategy. If declines persist alongside a lack of new negative catalysts, the next phase may be driven more by positioning and valuation than by fundamentals.

Why It Matters

  • Sharp intraday declines in high-profile biotech names can announcement cooling sentiment across the sector, even when no single company-specific catalyst is cited.
  • When biotech has rallied quickly, profit-taking can dominate near-term price action and increase volatility.
  • If weakness continues, investors may reassess the balance between pipeline expectations and near-term execution timelines.
  • For companies like Moderna and Myriad, trading remains sensitive to changes in risk appetite even when fundamental information is unchanged.

Sources

Key Facts

  • Myriad Genetics and Moderna shares fell during the afternoon session, according to a market report.
  • The pullback was framed as broader weakness across biotech and big pharma.
  • The report attributed the move to traders securing profits after a strong sector run.
  • The article did not point to specific new company events as the driver of the afternoon declines.

Healthcare Related

Myriad Genetics and Moderna slide as biotech profit-taking cools a powerful run | The Apex Times